Screener
Gyre Therapeutics, Inc. GYRE Noncontrolling interests in subsidiaries
Noncontrolling interests in subsidiaries at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:MinorityInterest.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Additional paid-in capital | 240,644 | 172,819 |
| Statutory reserve | 3,648 | 3,098 |
| Accumulated deficit | (137,962) | (112,603) |
| Accumulated other comprehensive income (loss) | 1,492 | (908) |
| Total Gyre stockholders’ equity | 107,928 | 62,497 |
| Noncontrolling interest | 34,561 | (2,952) |
| Total equity | 142,489 | 59,545 |
| Total liabilities, Series B preferred stock, redeemable convertible preferred stock, and stockholders’ equity | $199,255 | $219,763 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s noncontrolling interests in subsidiaries?
- Gyre Therapeutics, Inc. (GYRE) reported noncontrolling interests in subsidiaries of $34.56M in Q2 2026.
- How has Gyre Therapeutics, Inc.'s noncontrolling interests in subsidiaries changed year-over-year?
- Gyre Therapeutics, Inc.'s noncontrolling interests in subsidiaries decreased by 7.6% year-over-year, from $37.42M to $34.56M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s noncontrolling interests in subsidiaries?
- Over 3 years (2022 to 2025), Gyre Therapeutics, Inc.'s noncontrolling interests in subsidiaries has grown at a -53.7% compound annual growth rate (CAGR), from $29.7M to -$2.95M.
- What does noncontrolling interests in subsidiaries mean?
- This represents the portion of a subsidiary's net assets that is owned by outside shareholders rather than the parent company. It is reported within equity to show the total value of the subsidiary's assets and liabilities that are not attributable to the parent. It reflects the non-controlling stake in consolidated entities.
Ask your AI about Gyre Therapeutics, Inc.'s noncontrolling interests in subsidiaries.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude